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ABSTRACT 
Important aims of cancer proteomics include gaining better understanding of cancer 
biology and identifying cancer biomarkers. Mass spectrometry (MS) based shotgun 
proteomics allow for identification and quantification of thousands of proteins in 
complex human samples. However, proteomics discovery research in clinical material 
faces many challenges. The biological differences between groups are often expected 
to be rather small, at the same time the human proteome is highly complex and there 
is large biological variation between clinical samples. To be able to extract 
meaningful results from proteomics data derived from biological and clinical 
material, care has to be taken to all the critical steps in the data analysis workflow. 
First of all we need to have robust methods to extract good quality data. A proper 
statistical analysis is then of outmost importance, taking into account risks of over-
fitting and false positives. In addition, we also need system based approaches to relate 
the data to clinical and biological questions.  
 
The main goal of this thesis was to generate robust methods for selection of key 
proteins, networks and pathways relevant for answering biological and clinical 
questions. The work includes development and evaluation of workflows for 
quantitative analysis of proteomics data. 
 
In paper I, a multivariate meta-analysis workflow was developed to link existing 
proteomics data from human colon and prostate tumours. The aim was to identify 
proteins distinguishing between normal and tumour samples independent of tissue 
origin, as well as to find unique markers. The bioinformatics workflow for meta-
analysis developed in this study enabled the finding of a common protein profile for 
the two malign tumour types, which was not possible when analysing the data sets 
separately. The purpose of paper II was to generate a basis for the decision of what 
protein quantities are reliable and find a way for accurate and precise protein 
quantification. We developed a methodology for improved protein quantification in 
shotgun proteomics and introduced a way to assess quantification for proteins with 
few peptides. The experimental design and developed algorithms decreased the 
relative protein quantification error in the analysis of complex biological samples. In 
paper III, we presented SpliceVista, a tool for splice variant identification and 
visualization based on MS proteomics data. SpliceVista identifies splice variant 
specific peptides and provides the possibility to perform splice variant specific 
quantitative analysis. SpliceVista was applied in two experimental datasets to 
exemplify its capability of detecting differentially expressed splice variants at the 
protein level. The aim of paper IV was to develop a network based analysis 
workflow for proteomics data to identify protein subnetworks with different activity 
between groups of samples. The methodology, which is based on a multivariate 
model directed by the network, was applied to several of our clinical mass 
spectrometry datasets. The output from the subnetwork analysis was functional 
subunits of proteins, rather than a collection of sparse proteins, which were shown to 
more readily provide a model of the biological mechanisms studied, and thus aid in 
the biological interpretation. 
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1 BACKGROUND 
1.1 PROTEOMICS 
The proteome is the entire set of proteins expressed by a genome, cell, tissue or 
organism at a certain time, under certain conditions [1, 2]. The term proteomics 
describes the large-scale study of the proteome; including protein composition, 
protein structure, expression, function and interactions. The Human Genome Project 
[3, 4] provided a blueprint for the gene-encoded proteins potentially active in human 
cells, but there is still limited knowledge on the majority of the around 20 000 
protein-coding genes. The Human Proteome Project [5, 6] was launched in 2010 with 
the goal of mapping the entire human proteome. Doing this is a formidable task, the 
total number of different proteins in the human proteome is estimated to be around 1 
million [7, 8] (Figure 1). Further, in contrast to the genome, the proteome is much 
more dynamic and in constant change. Proteins are expressed at distinct times, in 
distinct cell types and only under certain conditions, as well as undergo differential 
splicing and post-translational modifications. This means that even the basic set of 
proteins that are produced in a cell needs to be determined. 
 
 
Figure 1. The DNA to RNA to protein complexity. Each gene can give rise to multiple mRNA 
transcripts by using alternative promoters, alternative transcription termination sites, alternative splicing 
and mRNA editing. The number of different protein variants from one gene is further increased by the 
various protein post-translational modifications.  
 
The mRNA level is often measured as a proxy for the protein levels. Studies of 
differential mRNA expression are informative, but the mRNA level has been found to 
have limited correlation with the protein level [9, 10]. It is now known that mRNA is 
not always translated into protein, and the amount of protein produced for a given 
amount of mRNA depends both on the individual gene and on the current 
physiological state of the cell. Differences in protein synthesis and degradation also 
complicate the comparison, as mRNA and protein levels result from the coupled 
processes of synthesis and degradation. In addition, studies of RNA levels have 
limitations regarding information on protein function and interaction, and lacks 
information on post-translational modifications. Proteomics experiments confirm the 
presence of the specific protein and provide a direct measure of the protein quantity in 
a cell at a given time and condition. Another advantage of proteomics is that often the 
identified protein is the biological executive unit.  
 
1.1.1 Cancer proteomics 
Cancer proteomics is the study of protein changes related to cancer. For revealing 
signalling pathways causing cancer or other diseases, protein level measurements are 
particularly informative since protein mediated signalling controls the majority of 
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cellular events. The importance of proteins in human diseases can further be 
illustrated by the fact that a majority of all drugs are targeted to have an effect on 
proteins [11]. 
 
Tumorigenesis in humans is a multi-step process; the steps reflect genetic alterations 
that drive the transformation of a normal cell into a cancer cell. The hallmarks of 
cancer comprise six biological capabilities, essential for the development of 
malignant cancer: sustaining proliferative signalling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis [12]. Two additional emerging hallmarks have 
been proposed: reprogramming of energy metabolism and evading immune 
destruction [13]. During the transformation of a normal cell into a malignant cell, 
several changes occur at the protein level, including altered expression, differential 
protein modification, as well as changes in activity and localization. Identifying and 
understanding these changes is the main goal in cancer proteomics [14, 15]. Despite 
major progresses in detection and therapy, cancer remains a major public health 
challenge. Cancer is a leading cause of death worldwide, about 12.7 million cancer 
cases and 7.6 million cancer deaths were estimated for year 2008 [16]. A better 
understanding of the development of drug resistance, as well as development of 
biomarkers for the early detection and selection of the most effective therapeutic 
strategies, are urgently needed [17, 18]. 
  
1.1.2 Clinical and Biological discovery research 
The purposes of studying the proteome in relation to cancer can be several, but there 
are two main starting points: to gain better understanding of the cancer biology or to 
identify cancer biomarkers. Biological studies are often performed in model systems 
such as cell lines or animal models, while biomarker studies are preferably performed 
in clinical materials. Biomarkers are biological molecules that are indicators of a 
biological state. A biomarker can be used to provide an early indication or detection 
of the disease (diagnostic marker), to monitor disease progression and tell something 
about the disease outcome (prognostic marker) and to tell how a patient will respond 
to a treatment (predictive marker) [18]. Biomarkers based on the individual genetic 
make-up of patients can be used to design tailored treatment, an approach called 
personalized medicine. Personalized medicine is very important for cancer treatment, 
since population based medicine has not been successful for many cancer types [19]. 
Currently, it is very difficult to predict which patient will respond well to a treatment, 
as tumours often develop resistance to drugs. Development of therapy related 
biomarkers to select the most effective treatment, as well as diagnostic biomarkers to 
enable early diagnosis are key aspects to improve prognosis and survival for cancer 
patients [14, 15]. 
 
Recent advances in genomics and proteomics technologies have gained a lot of 
interest and expectations in the quest for cancer biomarkers. Unfortunately, the 
biomarker discovery research has so far mainly failed to deliver biomarkers for 
clinical use [19]. Omics technologies such as proteomics and DNA microarrays have 
generated more than 150 000 papers on putative biomarkers, but less than 100 have 
been validated for clinical practice [20].  
 
Proteomics discovery research in clinical material faces many challenges [21, 22]. A 
big challenge is small sample cohorts in combination with large and unknown 
complexity of the human proteome as well as large biological variation between 
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clinical samples. This is due to normal variation between healthy individuals as well 
as disease heterogeneity. Another complicating factor is that the differences in protein 
levels between groups might be very small, sometimes even smaller than the normal 
biological variation. Further, the low concentration of potential protein biomarkers 
[23, 24] makes biomarker discovery difficult, since most proteomics technologies are 
biased towards the detection of high abundant proteins. A number of key factors 
causing biomarker discovery to fail have been identified [19, 20]. Many of those can 
be explained by the influence of bias, the existence of a hidden structure in the data 
making the marker appear promising. Bias has been suggested to be the single biggest 
threat to validity of biomarker studies [25, 26], mainly because there are so many 
different sources of bias that can be difficult to keep control of. Furthermore, the 
observational design used in biomarker research is more subject to bias; subjects are 
selected and not randomly assigned, and baseline equality between cases and controls 
can most often not be assured. Many other factors can be explained by the use of 
inappropriate statistical methods. In high dimensional data there is a risk of over-
fitting the statistical model to the data, giving overly optimistic results. Another risk 
of analysing data with thousands of variables, and often few subjects, are the false 
positives, positive results that occur just by random events.  
 
Failures in biomarker development cost a lot, in terms of money, time, labour, talent, 
and reliability for the research field. To overcome the main obstacles for biomarker 
research and to increase the chances of taking a biomarker into clinic, the study has to 
be planned and executed carefully [21]. The selection of samples to include and a 
valid experimental design trying to avoid any possible bias is crucial. The 
experimental platform need to be suitable for the type of material and measurements, 
and the performance of the assay, in terms of sensitivity, accuracy and robustness, 
should be known. The technical, experimental and biological variation of the system 
has to be assessed and considered in the handling of the quantitative data. A proper 
statistical analysis is of outmost importance, taking into account risks of over-fitting 
and false positives. Testing thousands of hypotheses simultaneously requires methods 
for multiple testing correction to keep control of the false discovery rate. Further, the 
statistical model and the biomarker have to be validated properly, preferably in an 
independent sample cohort using an orthogonal technique. Hence the analytical 
properties of the validation method also have to be taken into account.  
 
1.2 PROTEOMICS TECHNOLOGIES 
As mentioned above, there are several analytical challenges in studying the human 
proteome, as compared to studying the genome (DNA) or the transcriptome (RNA). 
Besides the size and complexity of the human proteome, there are large differences in 
protein abundance, spanning over ten orders of magnitude in human plasma [23, 27] 
and at least six in tissue. Proteins are also chemically more heterogeneous than DNA 
and RNA and differ largely in solubility, size and pI. Those challenges put high 
demands on the methods used for proteomics analysis, to be able to cover as much as 
possible of the human proteome and also be able to reach the low abundant proteins. 
 
The main analytical techniques aiming at studying the proteome have traditionally 
been two-dimensional gel electrophoresis (2DE) together with mass spectrometry 
(MS). In 2DE, proteins are separated in two dimensions based on isoelectric point 
(pI) and size (Mw) (Figure 2A) [28]. The gel is stained and protein spots of interest 
can be cut out and identified using MS. The 2DE technique has limitations such as 
limited throughput, low dynamic range and low resolution; a typical 2DE experiment 
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detects approximately 2000-3000 protein spots out of which only a subset will be 
identified [29-32]. Today liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS) is a commonly used method to study protein expression 
on a proteome/genome wide scale. The peptides, proteins or other analytes eluting 
from the LC column are separated according to their mass-to-charge (m/z) ratio by 
the mass spectrometer (Figure 2B). Recent developments in methods and instruments 
for mass spectrometry enable large scale quantitative proteomics analysis of complex 
samples with very good coverage [10, 33-42]. The number of samples feasible to 
analyse by MS is however limited by low throughput. At present, some publications 
have reported over 10 000 proteins identified and quantified in human cell lines [43-
45]. The developments have also enabled the quantification of complete proteomes of 
model organisms such as yeast [46-49]. The technical advances have moreover made 
MS based proteomics an important tool for biomarker discovery [24, 50-58]. In 
addition to mass spectrometry methods, affinity based proteomics methods using 
antibodies are also widely used to study protein levels, protein localization and 
protein interactions [59-63]. 
 
 
Figure 2. A: Two-dimensional gel electrophoresis. Proteins are separated in two dimensions based on 
isoelectric point (pI) and size (Mw). Protein spots of interest can be cut out and identified using MS/MS. 
B: Liquid chromatography coupled to tandem mass spectrometry. Peptides are usually fractionated by 
charge or here by pI, followed by separation by hydrophobicity (retention time in LC column) and by 
mass-to-charge ratio (m/z) in tandem mass spectrometry, first on peptide ions in MS1 and secondly on 
fragmented peptides in MS2 (see Figure 3). 
 
1.3 MASS SPECTROMETRY 
Mass spectrometry (MS) is an analytical technique that separates molecules according 
to their mass-to-charge ratio (m/z) [35, 64, 65]. It can be used for determining masses 
of particles, determining the elemental composition of a sample or molecule, and for 
elucidating the chemical structures of molecules, such as peptides, proteins, 
metabolites or other chemical compounds. In proteomics, MS can be used for protein 
quantification, protein identification, identification of protein modifications and 
protein complexes, as well as protein localization (imaging) [36, 66-68]. 
 
MS instruments consist of three major modules: an ion source, a mass analyser and a 
detector (Figure 3). In the ion source, the analytes are ionized and brought into gas 
phase. The most commonly used ion sources in proteomics are electrospray ionization 
(ESI) or matrix assisted laser desorption ionization (MALDI). The mass analyser 
separates the ions based on their m/z ratio, by applying electromagnetic fields. 
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Orbitrap and ion cyclotron resonance (ICR) separate ions based on m/z resonance 
frequency, quadrupoles (Q) and ion traps (IT) separate ions based on stability of their 
paths in oscillating electric fields and time of flight (TOF) analysers use flight time. 
Once separated by m/z, the detector measures the number of ions hitting the detector 
and provides the data for calculating the abundance of each ion cloud present. The ion 
signal is processed into a mass spectrum, with m/z on x-axis and ion count on y-axis. 
 
 
Figure 3. Major modules of tandem mass spectrometers. In the ion source the analytes are ionized. The 
mass analyser separates the ions based on m/z ratio. In shotgun proteomics, the first analyser (MS1) 
separates the peptide ions (precursor ions), peptides are then fragmented by collision energy (here 
exemplified by CID, collision induced dissociation) and the fragment ions (product ions) are separated by 
the second analyser (MS2). The detector measures the number of ions for a certain m/z ratio, which is 
used for the generation of the mass spectrum. 
 
1.3.1 Shotgun proteomics 
There are two main strategies for mass spectrometry based proteomics: bottom-up 
and top-down. In a top-down approach, intact proteins are analysed directly by mass 
spectrometry. Measuring intact proteins directly in MS on a larger scale is limited to 
rather small proteins (<45 kDa). Another problem of analysing intact proteins is that 
they have very different properties, making some proteins difficult to solubilize, 
separate and ionize by MS. 
 
In a bottom-up approach, proteins are enzymatically digested into peptides, which are 
analysed by mass spectrometry [7, 40, 69-71]. Bottom-up, also known as shotgun 
proteomics, is the far most common workflow in MS based proteomics. A typical 
quantitative shotgun proteomics workflow in our lab is depicted in Figure 4. 
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Figure 4. Quantitative shotgun proteomics workflow. Proteins are digested to produce a peptide 
mixture. The peptides are labelled, pooled and pre-fractionated. Fractions are loaded onto a nano 
column and the peptides are separated by reverse phase chromatography. As the peptides elute from 
the column, they are subject to tandem mass spectrometry analysis. The MS1 and MS2 spectra yield 
peptide identifications, which are used to infer proteins. The reporter ions from the labels are used for 
relative quantification of peptides. Peptide ratios are then summarized into protein ratios. Statistical 
analysis is performed to select the most important proteins for further systems biology based analysis 
to infer biological interpretation.   
 
Shotgun proteomics is based on enzymatic cleavage of proteins into peptides (usually 
by trypsin). This is performed to facilitate ionization and fragmentation. It further 
avoids problems associated with intact protein analysis, such as poor separation 
efficiency and poor sensitivity. 
 
The level of sample complexity, and protein abundance range, influences the 
performance of the MS analysis. It is difficult to obtain optimal ionization and 
fragmentation process for all analytes in complex samples, since the analytes have 
very different chemical properties. In addition, MS has limited dynamic range of 
detection, limiting sensitivity and quantification in complex samples. To overcome 
these challenges, and to maximize protein identifications, various steps directed at 
reducing sample complexity can be performed prior to MS analysis [64, 72, 73].   
 
The most common approach to reduce sample complexity is by pre-fractionation, 
performed either on protein or peptide level. Since the sample complexity is increased 
by enzymatic cleavage (by a factor of about 40), pre-fractionation on peptide level is 
particularly valuable. By pre-fractionation, the peptide sample can be fractionated 
according to its physicochemical properties such as charge, isoelectric point, 
hydrophobicity or a combination of these. Alternatively, specific subsets of the 
sample can be targeted through enrichment of peptides or proteins using affinity-
based resins or antibody-based immunoprecipitation. 
 
To further reduce complexity of the peptide mixture, the peptides are subjected to 
separation prior to MS analysis. The separation is required to detect low-abundance 
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proteins that would otherwise be overshadowed by higher abundance signal, as well 
as for un-ambiguous identifications. A common setup is to couple a liquid 
chromatography system (LC) to a mass spectrometer. 
 
Peptides eluting from the LC column are then analysed by tandem MS. The peptides 
are ionized and analysed by the first MS, generating the peptide ion spectrum (MS1). 
For each MS1 scan, the top 5-10 peaks are usually fragmented and subjected to the 
second MS scan generating the fragment ion spectrum (MS2) [74]. 
 
The raw data (MS1 and MS2 spectra) generated by the instrument is first processed 
by signal processing softwares to reduce the raw data into a set of peaks [75, 76]. 
 
Peptide identification is typically accomplished by matching the experimental MS2 
spectra to in-silico predicted spectra generated by a theoretical digest of a protein 
database, using the precursor ion mass as support. The peptide spectrum matches 
(PSMs) are then summarized into protein identities. 
 
Peptide quantification can be performed either based on the MS1 spectra, as in label-
free quantification, or based on the MS2 spectra, as in quantification based on 
isobaric labels. 
 
The major advantage of shotgun proteomics is the ability to identify and quantify 
thousands of proteins in a single analysis. One disadvantage is the informatics 
challenges related to processing the large amount of acquired data [76]. A shotgun 
proteomics approach is most suitable for discovery projects aiming at rapid 
identification, and relative quantification, of complex sample mixtures in a limited 
number of samples. It is a hypothesis generating experiment that requires several 
follow up steps using alternative techniques. Typically, the proteins identified in the 
discovery phase would be validated with more targeted approaches like selected 
reaction monitoring (SRM) mass spectrometry [77-80] or affinity based proteomics 
[63, 81] in a larger cohort.  
 
1.3.1.1 Labelling and Quantification 
Many proteomics studies aim at studying differences in protein expression levels 
between different conditions. Such comparative analysis depends on protein 
quantification [69]. As mentioned before, two principally different approaches exist 
for quantification by MS: label free methods and methods based on stable isotope 
labelling [82-85].  
 
Label free quantification is based either on the mass spectrometric signal intensity in 
MS1 for any given peptide, or on spectral counting; using the number of times the 
peptides from certain proteins are detected as a proxy for protein abundance [86-89].   
 
An advantage of isotopic labelling is that it enables pooling of samples, thereby 
reducing MS run time as well as technical variability. ICAT [90], iTRAQ [91], TMT 
[92] and SILAC [93] are among the most commonly used labelling methods based on 
stable isotopes. iTRAQ (isobaric tags for relative and absolute quantification) allow 
for simultaneous relative quantification of up to eight samples within a single run. 
Using iTRAQ labelling, fragmented reporter ions from the tag are used for relative 
quantification in MS/MS mode. 
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1.3.1.2 Peptide identification 
Modern MS instruments generate an enormous amount of fragment ion spectra per 
hour of data acquisition. The fragment ion spectrum of a peptide ion needs to be 
assigned to a peptide sequence. There are several different computational approaches 
to do this [94-98]: i) Database searching; experimental fragment ion spectra are 
matched with predicted spectra based on theoretical digest of protein sequences. 
Experimental spectra can also be used; in this case fragment ion spectra are matched 
to libraries containing experimental MS/MS spectra identified in previous 
experiments (Spectral library search), ii) De novo sequencing; peptide sequences are 
explicitly read out directly from the fragment ion spectra, iii) Hybrid approaches; 
database searching assisted by de novo sequencing. 
   
1.3.1.3 Protein identification 
The purpose of most proteomics experiments is the identification, and quantification, 
of the proteins present in the sample prior to digestion. Peptide sequences identified 
by a shotgun proteomics experiment thus need to be assembled into proteins. This is 
not straightforward due to several reasons [99, 100]. The major cause is peptide 
sequences shared between several proteins, leading to ambiguities in the 
identification process. The presence of several proteoforms (protein variants) [101], 
often with very similar protein sequences, further complicates the process. Commonly 
the parsimony principle (Occam’s razor) is used to infer proteins [102]; it determines 
the smallest number of proteins that can account for all observed peptides. 
 
1.3.1.4 Proteoforms 
Protein post-translational modification increases the functional diversity of the 
proteome by the covalent addition of functional groups to proteins, proteolytic 
cleavage of regulatory subunits or degradation of entire proteins. Post-translational 
modifications are key mechanisms to increase proteomic diversity. The total number 
of protein variants in the human proteome is estimated at over 1 million [8]. Protein 
isoforms also arise due to alternative splicing of the mRNA. Eukaryotic genes consist 
of exonic (protein coding) and intronic (non-coding) regions, after transcription the 
introns are removed by a process called splicing. Alternative splicing allows for the 
production of a variety of different proteins from one gene, by splicing and 
reconnecting exonic sequences in alternative ways to produce mature mRNA [103]. 
Alternative splicing is a very prevalent process in the human genome, it is estimated 
that around 92-94% of human genes has the potential to undergo alternative splicing 
[104]. It thus has great significance in increasing the proteome diversity and 
complexity. Alternative splicing plays an important role in regulating gene 
expression; it determines binding properties, intracellular localization, enzymatic 
activity, protein stability and posttranslational modifications of a large number of 
proteins. Disruption of alternative splicing events has been implicated in a large 
number of diseases, such as neurodegenerative, cardiovascular, respiratory and 
metabolic diseases, as well as several cancer types [105-107].   
 
1.4 QUANTITATIVE DATA ANALYSIS 
Once the peptide sequences have been determined and assembled into protein groups 
and the quantitative measurements have been defined both on peptide and protein 
level (see more details in sections 2.2.6 and 2.2.7), the analysis of the quantitative MS 
data can take place. 
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To extract meaningful results from MS proteomics data on biological and clinical 
material, care has to be taken to all the critical steps in the quantitative data analysis 
workflow, from handling the raw data to the statistical analysis and the biological 
interpretation of the result [70, 108-111]. The data analysis part is specifically 
delicate in large scale omics experiments since often thousands of variables are 
measured for only a few samples [112]. This implies a risk in the statistical analysis 
step to generate false positive discoveries. Further, the data often harbours a large 
amount of noise, in terms of biological variation, technical variation as well as 
experimental variation. The first important step is to know the quality of the 
quantitative data, to be aware of the limitations and reasonable expectations. 
Secondly, a suitable statistical method has to be selected and the statistical validation 
of the result has to be done carefully. 
 
1.4.1 Pre-processing and Quality control 
Prior to any statistical analysis the quantitative mass spectrometry data has to be pre-
processed and quality controlled. The quantitative data from an iTRAQ experiment is 
expressed as ratios between iTRAQ channels, since the iTRAQ reporter ions are used 
for relative quantification of each peptide. Often the ratios are log transformed to give 
the up- and down regulations equal importance, prior to statistical analysis. Further, 
the quantitative data need to be normalized to make samples and experiments 
comparable. The amount of missing values in the data also has to be assessed and 
proteins with a large amount of missing data points might have to be excluded prior 
to statistical analysis. 
 
Quality control of the quantitative data also has to be performed; this can be done by 
investigating the distribution of the data and missing values. A useful plot for 
investigation of data distribution, data separation and outliers is the PCA (Principal 
Component Analysis) scores plot (see section 1.4.2.3). For detecting differences in 
the distribution between samples or pools of samples, the boxplot can be very useful 
(see example in Figure 5). The purpose of the quality control is to detect problems in 
the quantitative data such as biases in data distribution, which can then be adjusted 
for by normalization prior to statistical analysis.  
 
 
Figure 5. Example of a boxplot for protein expression data from two clinical sample groups: control and 
recidiv (relapse). The intensities of all proteins for one sample are plotted in each column. The horizontal 
line marks the median intensity for each sample, the boxes covers the mid 50% of data, spanning from 
the first quartile to the third quartile. The upper and lower vertical lines marks a 95% confidence interval 
for the median and the circles outside the lines are thus outliers.  
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1.4.2 Statistical analysis 
In a large scale proteomics experiment we regularly start with thousands of variables, 
although we expect only a small fraction of those to be interesting for the biological 
or clinical question. The purpose of the statistical analysis is to extract the 
variables/proteins that are important for the clinical or biological question at task 
[113]. Most often the goal is to do a group comparison of samples from different 
conditions. Statistical methods for group comparisons can be divided into univariate 
methods, that test one variable at a time, and multivariate methods, that test all 
variables simultaneously. 
 
1.4.2.1 Univariate methods 
The most commonly used univariate method for group comparison is the student’s t-
test, which compares the distribution of a variable between two groups of samples. T-
test exists for one or two groups. For more than two groups the ANOVA is an 
alternative. Both t-test and ANOVA are parametric which mean they rely on certain 
assumptions about the data – that it is normally distributed and has a homogenous 
variance (homoscedasticity). If those assumptions are not met, there exist non-
parametric methods for both two group (Mann Whitney) and multiple group 
comparisons (Kruskal-Wallis). 
 
1.4.2.2 Multiple testing problem 
The significance level of a hypothesis test is often expressed in terms of p-values. The 
p-value indicates the probability that the relationship or difference found in the 
sample occurred by chance and is used to control the type I error (false positives) 
[112]. In proteomics studies, where many proteins are tested simultaneously, the 
probability of committing a type I error increases dramatically. The problem is that 
the standard hypothesis test is designed to control the type I error of each test at 
certain significance level. As the number of independent tests increase, the likelihood 
of observing data that satisfies the rejection criterion by chance alone increases (type 
I errors). To control the experiment-wise error rate, alternative measures of error are 
needed in those cases [112, 114]. Commonly used measures of error in multiple 
testing procedures are family wise error rate (FWER), the probability of at least one 
type I error, and false discovery rate (FDR), the expected proportion of type I errors 
among the declared significant results. 
 
There are two main approaches for controlling the experiment wise error rate: 
Methods for controlling the FWER, like the Bonferroni method [115], and methods 
for controlling the FDR, like the Benjamini & Hochberg step down method [116]. 
Methods to control FWER are appropriate when you want to guard against any false 
positive. However, in many cases (particularly in omics discovery experiments) this 
is too conservative and a certain number of false positives can be tolerated. In these 
cases, the more relevant quantity to control is the false discovery rate (FDR). 
Furthermore, controlling FWER may lead to a very high rate of false negatives (type 
II error). 
 
1.4.2.3 Multivariate methods 
If the phenotype or biological process studied is thought to be effected by several 
variables/proteins in combination, a multivariate approach is often more appropriate 
than a univariate. The strength of multivariate methods is the possibility to define 
combinations of variables that maximizes the model predictive ability. Characteristics 
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of proteomics experiments are thousands of variables (features) and small sample 
size. This is called the high-dimensional small-sample problem, which causes several 
statistical methods to fail or perform sub-optimal [113, 117]. Therefore, dimension 
reduction is often a necessary step in the analysis of proteomics data. Dimension 
reduction can be divided into feature selection and feature extraction 
(transformation). Feature selection methods reduce the number of features by 
excluding irrelevant or redundant features. Feature extraction methods identify a new 
set of features by transforming or combining the old features [117]. 
 
Commonly used multivariate methods for dimension reduction, variable selection and 
classification are Principal Component Analysis (PCA) and Partial Least Squares 
(PLS). PCA and PLS can handle high dimensionality of the data, as well as the 
presence of a large amount of biological noise. PCA is an unsupervised method [118], 
useful for getting an unbiased overview of the data as well as to detect trends and 
outliers. A PCA model is generated by introducing a new set of variables, which 
maximize the variance of a linear combination of the original predictor variables. The 
new variables, called principal components, represent directions in the data 
demonstrating the highest variation (Figure 6). This might of course be distinctly 
different from the directions best separating the classes. PLS regression is a 
supervised multivariate method for assessing the relationship between a descriptor 
matrix X and a response matrix Y [119, 120]. PLS takes the classes in the data into 
account and finds new variables by maximizing the covariance between the response 
variable and a linear combination of the predictor variables (see more details in 
section 2.2.8). 
 
 
Figure 6. Schematic figure of principal component analysis for a simple case of three predictor variables 
(x1, x2, x3). The PCA model is generated by introducing a new set of variables, which maximize the 
variance of a linear combination of the original predictor variables. The new variables, called principal 
components (PC1 and PC2), represent directions in the data demonstrating the largest variation. 
 
1.4.2.4 Model validation 
Any statistical model needs to be validated, to assess the stability and generalizability 
of the model [113]. In an optimal scenario a completely new set of samples would be 
used to test the model performance on. In most cases, this is not possible due to few 
samples available. An alternative way to validate the model, which is commonly 
used, is cross-validation. In a k-fold cross-validation the data is randomly divided into 
k parts. The model is built and optimized on k-1 of the parts and tested on the 
excluded part. This is repeated for all the k parts and average model performance is 
calculated. During cross-validation it is important to remember to handle replicates 
together; otherwise one might risk receiving overly optimistic model performance.  
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1.5 BIOLOGICAL INTERPRETATION 
The output of a statistical analysis of proteomics data is one or more lists of proteins 
that show an interesting change in level in the context of the experiment. This is not the 
end point of the analysis, but the starting point of a very complex process of deriving 
biological interpretation. The biological interpretation aims at placing the selected 
proteins into a context, to lift the analysis from individual molecules to the biological 
system level. During the biological interpretation process, the molecular expression 
data from the proteomics experiment is coupled with the vast information held in public 
knowledge databases [121, 122]. 
 
1.5.1 Systems Biology 
To enable the leap from data analysis to biological interpretation, system based 
approaches integrating multiple data types are crucial. Systems biology is the study of 
systems of biological components, with the focus on complex interactions between 
the components [123-126]. Living systems are dynamic and complex and their 
behaviour are hard to predict from the properties of the individual parts. 
 
Biological processes are often driven by modules of proteins working together rather 
than individual genes or proteins. Several comprehensive studies, mostly in cancer, 
have shown very few genes that have a robust and significant differential expression 
pattern across different sample cohorts [127, 128]. However, many of the sample 
cohorts showed similar differentially regulated pathways [129-132]. By moving the 
omics field from single molecules to affected pathways or network modules, we can 
generate models of the system which are more readily interpretable as well as more 
robust. 
 
1.5.2 Networks and Pathways 
Networks are built up by components (nodes) and interactions (edges) between them. 
The interaction can be almost any kind of association and can be directed or 
undirected. For example is a protein-protein interaction network built up by proteins 
(the nodes) and the physical interactions between them (the edges) [133]. Pathways 
are also networks, the difference lays in the level of annotation or understanding. 
Typically pathways are well-defined parts of the network that relates to a known 
physiological process or complete function, for example Glycolysis, Amino acid 
metabolism or Cell cycle. There are numerous databases available for networks and 
pathways. For a comprehensive listing of biological pathway and molecular 
interaction related resources see www.pathguide.org [134]. 
 
Biological networks have shown to be very different from random networks 
(randomly connected molecules); they apply to some basic organizing principles in 
their structure and evolution. For example, biological networks show a high degree of 
clustering and presence of a few highly connected nodes (hubs) that hold the network 
together [135]. By the use of networks and pathways we can integrate different types 
of molecular expression data and form modules of biologically related proteins. The 
network is the backbone, placing the molecules into a topological context. Molecular 
expression data on the other hand, has quantitative measurements of the molecules in 
a sample under different conditions. The integration of those different sources of 
information (i.e. expression data and networks) holds great potential to give new 
insights into disease biology [135-137]. 
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1.5.2.1 Regulated subnetworks 
Several methods have been developed to integrate expression data with interaction 
maps or pathway databases with the aim to identify subsets of the network 
(subnetworks) that associates with biological or clinical outcome. The subnetworks 
are sets of interacting proteins whose combined expression data can predict or 
classify samples. Numerous recent publications have shown that the predictive 
performance of expression data can be improved by the incorporation of interactome 
data [138-140]. Compared to traditional individual marker genes, the identified 
subnetwork markers had several advantages, as they more readily provide models of 
molecular processes and are more robust and predictive [138]. 
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2 THE PRESENT STUDY 
2.1 AIMS 
The overall aim of this thesis work was to generate robust methods for selection of key 
proteins, networks and pathways relevant in relation to biological and clinical 
questions, using vast experimental proteomics data as starting point. This includes 
development and evaluation of methods for quantitative analysis of proteomics data, 
proceeding from setting adequate limits of quantification to statistical data analysis 
methods and system based approaches for integrating several types of data, towards the 
goal to generate biologically and clinically relevant information. 
 
The specific aims of the papers I-IV were: 
 
Paper I: To develop a multivariate meta-analysis workflow to couple 2DE data from 
colon and prostate human tumours, to identify common and unique protein patterns for 
the two tumour types.    
 
Paper II: To develop a methodology for improved protein quantification in shotgun 
proteomics data and introduce a way to assess quantification errors for proteins in 
complex biological samples.  
 
Paper III: To develop a tool for splice variant identification and visualization based on 
MS proteomics data, to provide the possibility to perform splice variant specific 
quantitative analysis. 
 
Paper IV: To develop a multivariate network based analysis workflow for proteomics 
data to identify subnetworks with different activity between groups of samples, to 
enable detection of differences on a biological system level and to further enhance the 
interpretation of results from cancer studies. 
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2.2 MATERIALS AND METHODS 
This section describes some selected key methods and aspects applied in papers I-IV. 
The materials and methods are described in detail in each paper.  
 
2.2.1 Samples and Study design 
Proteomics data from both cancer cell lines and tumour material was used in the present 
study. Paper I includes 2DE data on samples from human prostate and colon tumours. 
The approach in paper II was first evaluated on a standard dataset of A549 cell lysate 
mixed in the proportions 2:2:1:1:2:2:1:1 (see experimental setup in Figure 7). To 
demonstrate the usability, the methodology was also applied to another cancer cell line 
experiment as well as in a clinical dataset of lung cancer tissue samples. To exemplify 
the capability of the software developed in paper III, the method was applied on an 
experimental dataset of A431 cell line treated with Gefitinib. The analysis developed in 
paper IV was tested on different complex biological datasets, both cell line samples 
and clinical samples. 
 
 
Figure 7. Experimental setup for standard dataset in paper II. Tryptic peptides from A549 cells were 
labelled with iTRAQ in a 2:2:1:1:2:2:1:1 ratio. Peptides were analysed by LC-MS/MS alone or pre-
fractionated before LC-MS/MS using narrow range immobilized pH gradient isoelectric focusing (IPG-
IEF). A mix of all peptides or extracted peptide fractions from the IPG-IEF were analysed on three 
different LC-MS platforms. 
 
2.2.2 Two-dimensional gel electrophoresis 
In paper I, data from two-dimensional gel electrophoresis (2DE) on prostate and colon 
tumours were subject to a multivariate meta-analysis. The proteins were separated in 
the first dimension of isoelectric focusing using immobilized pH-gradient (IPG) strips 
with a pH 4-7 linear gradient. The second dimension was performed using 10-13% 
linear gradient SDS/PAGE gels. The gels were then stained and scanned and the 
images analysed by the PDQuest software [141]. The two sample sets, prostate and 
colon, were first analysed separately in the software. The masters (image containing the 
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most spots) from the separate match sets were then matched to each other and thereby 
linked all the gels in the two data sets together. 
 
2.2.3 Isoelectric focusing 
In papers II, III and IV narrow range immobilized pH gradient isoelectric focusing 
(IPG-IEF) was used on peptide level to reduce sample complexity [142, 143]. On an 
IPG-IEF strip, the peptides are separated according to their isoelectric point. The 
complexity of the peptide mixture is thereby reduced by selectively analysing the sub-
fraction of peptides within a certain pI range. Different pH ranges can be used 
dependent on which fraction of the peptidome one would like to focus on. The acidic 
pH range (3.7-4.9) in these studies is chosen so that the complexity is reduced without 
any significant loss of proteome coverage [143]. The pI of identified peptides can 
further be used to validate the peptide sequence and to restrict the search database [144, 
145]. 
 
2.2.4 iTRAQ and TMT labelling 
Papers II, III and IV uses 8-plex iTRAQ based quantification of peptides. iTRAQ 
(isobaric tags for relative and absolute quantification) allow for quantification of up to 
eight samples within a single run. Using iTRAQ, fragmented reporter ions from the tag 
are used for quantification in MS/MS mode. The intact iTRAQ labels have the same 
mass and same MS properties. The individual tags are distinguished by their 
fragmentation patterns in MS/MS, giving rise to reporter ions of different masses that 
can be quantified in the MS/MS spectra. iTRAQ is primarily used for relative 
quantification, the ratio between the reporter ions within one spectrum is used for 
relative quantification of each peptide within one run. If more than eight samples are 
analysed, comparison between runs is necessary, for this one commonly uses an 
internal standard shared between the runs. Paper IV also includes one dataset with 
quantification by tandem mass tags (TMT). TMT is similar to iTRAQ, but the reporter 
ions have slightly larger mass and exist in six tags. 
 
2.2.5 Mass spectrometry instruments 
MS instruments consist of three major modules: an ion source, a mass analyser and a 
detector. Each type of MS instrument uses a different setup of those three modules. In 
papers II, III and IV an LTQ-Orbitrap [146, 147] was used for LC-MS/MS analysis. 
The LTQ-Orbitrap was coupled to a nano-ESI source that ionizes the peptides eluting 
from the LC column. LTQ-Orbitrap Velos [148] is a hybrid instrument with two 
different kind of mass analysers: a LTQ (Linear Quadrupole Ion trap) which separates 
ions based on stability of their paths in oscillating electric fields and an Orbitrap that 
separates ions based on m/z resonance frequency. This LTQ-Orbitrap thus combines 
the sensitivity and speed of the LTQ with the high mass accuracy and high resolution of 
the Orbitrap [146, 149]. 
 
In the LTQ-Orbitrap Velos, the peptide ion mass spectrum (MS1) is acquired with the 
Orbitrap. The fragmentation of the peptide ions can be done either in the ion trap, using 
collision induced dissociation (CID), or in the higher-energy collisional dissociation 
(HCD) chamber. The fragment ion mass spectrum (MS2) can then be acquired either in 
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the ion trap or in the Orbitrap. The low energy CID fragmentation results in an escape 
of many small ions (low mass range) leading to low quality spectra in the low mass 
region, where the iTRAQ reporter ions end up. Using the higher energy collision 
(HCD), the small ions stay and the quality of the spectra in the low mass region is 
good, thus the reporter ions can be used for quantification [150]. Optimal settings for 
the LTQ-Orbitrap Velos, regarding collision energy for HCD and fragmentation time, 
are investigated in paper II. 
 
In paper II, the performance of several different MS platforms were compared and 
data was also generated on a MALDI-TOF/TOF [151] and Q-TOF [152] system. 
Matrix assisted laser desorption ionization (MALDI) is a soft ionization method used in 
mass spectrometry. In MALDI the sample co-crystallizes with a matrix and is pulsed 
with a laser, which ionizes and vaporizes the analytes. The MALDI ion source is most 
often coupled to a time-of-flight (TOF) analyser, which uses flight time to separate 
ions. TOF/TOF is a tandem mass spectrometry method where two time-of-flight mass 
spectrometers are used consecutively to generate MS2 spectra. The Q-TOF is another 
hybrid instrument with a Quadrupole coupled to a time-of-flight analyser. Each 
instrument has its own advantages as well as disadvantages, and is suitable for different 
types of studies [35, 64]. 
 
2.2.6 Peptide and Protein identification 
2.2.6.1 Database search 
The output from tandem mass spectrometry analysis is precursor (peptide) ion spectra 
(MS1) and fragment ion spectra (MS2). The fragment ion spectra need to be assigned 
to peptide sequences to be able to infer which peptides, and thereby proteins, were 
present in the sample. The method for peptide identification used in papers II, III and 
IV was database search [153]. The database consists of all protein sequences 
downloaded from for example Ensembl (www.ensemble.org) [154]. The protein 
sequence is then theoretically digested by trypsin to generate peptide sequences. The 
database is then searched, using a search engine, for the peptide whose predicted 
spectrum best matches the observed spectrum. To limit the possible matches in a 
database search, the search is restricted by mass tolerance, proteolytic enzyme 
constraints, post-translational modifications and the m/z of the precursor ion (peptide).  
 
The output from a database search is a collection of peptide-spectrum matches (PSM) 
with an associated score. The score reflects the similarity between measured and 
predicted spectra. A number of different search algorithms and scoring schemes have 
been described in the literature [94, 95, 97], commonly used publically available tools 
are Mascot (used in paper II) and Sequest (used in paper III and IV). 
 
The peptide score depends on dataset, search algorithm and search parameters, which 
makes it very difficult to compare scores between search algorithms and datasets. 
Methods have been developed to provide statistical measures of confidence and 
estimates of error rate, which are independent of the scoring scheme used [94]. The 
statistical approaches can be grouped into two categories: target-decoy approaches 
[155] and empirical Bayes approaches [156, 157]. The target-decoy approach was used 
in papers II, III and IV. This approach is based on creating a decoy database, which is 
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a reversed or shuffled version of the target database, and then search the two databases 
with the same settings. Assuming that there is no overlap between the target and decoy 
databases and assuming that incorrect assignments from target and decoy sequences are 
equally likely, we do not expect to get any real matches from a decoy database. The 
number of matches found in the decoy database is thus a good estimate of the number 
of false positives present in the matches from the target database. The target-decoy 
approach gives robust and effective estimates of the number of incorrect identifications 
(FDR) for an entire dataset, but it does not remove incorrect identifications. With the 
use of the target-decoy approach one can select the score threshold needed to reach a 
certain FDR level (1% used in papers II-IV). 
  
Most often, the peptides identified by the database search are grouped into proteins, and 
one would therefore like to control the FDR at the protein level. But since errors 
determined at the PSM level, by target-decoy approach for example, propagate to 
protein identification level in a non-trivial manner, this is not a straight-forward task. 
One method for computing FDR at protein level is MAYU [158], which was used in 
paper II. 
 
Using a database search, only around 25-30% of the generated spectra can be explained 
successfully. The unexplained spectra can have several reasons, like for example poor 
quality spectra. One other big limitation is incomplete databases not containing all the 
protein variants present in the sample. This is specifically true for protein isoforms, and 
post translational modified proteins, which often are poorly covered in the traditional 
databases and search engines. 
 
2.2.6.2 Inferring protein 
Protein identifications are defined as assemblies of PSMs. The protein inference, which 
groups peptides into proteins, faces many challenges: many peptides group into 
relatively small number of proteins, incorrect spectral identifications match randomly 
to the large protein database and shared peptides make it difficult to separate out 
protein isoforms. Alternative splicing is a widespread event in the human genome, as 
much as around 90% of human genes undergo alternative splicing. Splice variants share 
peptide sequences to a large extent and is therefore difficult to separate out by database 
search.  
 
One method to try to increase the number of splice variants detected by mass 
spectrometry has been to include the sequence of known and predicted protein variants 
in the search database [159]. However, this method expands the searching space 
significantly, effecting searching time and risk of making false peptide discoveries. In 
paper III, an alternative method for identifying and quantifying splice variants in mass 
spectrometry based proteomics data is developed. The developed tool mines data from 
the alternative splicing database EVDB (Evidence Viewer Database) [160] and maps 
MS identified peptides to known splice variants. 
 
2.2.7 Peptide and Protein quantification 
In the current study (papers II-IV), the iTRAQ reporter ions are used for relative 
quantification of the peptides in each of the eight samples. The peptide ratios are 
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calculated by dividing each iTRAQ channel by the mean of the first two iTRAQ 
channels (113, 114). In papers II-IV, the peptide ratios are normalized to the same 
sample median on peptide level to make iTRAQ channels comparable, assuming that 
the peptide distribution is equal between samples. This assumption is also based on the 
fact that the protein amount loaded is equal for all samples. The protein ratios are also 
log2 transformed to bring low signals and high signals more together and to make up 
and down regulations equally important.  
 
The peptide ratios are then aggregated to yield protein ratios. The quantitative 
measurements on the peptide level have to be aggregated to protein quantification in a 
way that returns the best (most accurate and precise) protein quantification measure. 
Most methods for summarizing peptide data into protein data rely on a simple mean or 
median over the peptide ratios. By this method, low intensity signals or noisy data as 
well as wrongly assigned peptides may easily distort the computed protein ratios. A 
recent paper introduced a novel statistical estimator for protein ratios, generating 
improved protein quantification as well as a built-in quality control metric [161]. In 
paper II, some methods for summarizing peptide data into protein ratios are compared. 
The presence of several protein isoforms in the sample can potentially also cause 
incorrect protein ratios. If several unresolved protein isoforms are present, the protein 
ratio is a mixture of different protein species. Recently, a tool for Protein Quantification 
by Peptide Quality control (PQPQ), was developed [162]. PQPQ looks at the 
correlation pattern for peptides over iTRAQ channels to detect peptide clusters and 
outlying peptides and includes only correlated peptides in the calculation of the protein 
quantities. Paper III investigates the effect of unresolved protein isoforms by 
comparing the quantification based on gene centric, protein centric and splice variant 
centric analysis.  
 
In iTRAQ, systematic biases can arise because of differences in iTRAQ labelling 
efficiency and protein digestion. Recent studies have reported that iTRAQ data has 
issues with both accuracy and precision [163, 164]. Fold changes were underestimated 
and biased towards null. The precision was affected by variance heterogeneity, with 
higher variance for low intensity signals. This is a problem since low signals dominate 
the data sets and many proteins have only few peptide readings. Improved quantitation 
methods have been suggested, addressing the variance heterogeneity by excluding low 
intensity peptides [165], weighting peptide data by uncertainty [165-168] or stabilizing 
the variance [163]. In paper II, the errors in iTRAQ quantification is investigated and 
an improved method for protein quantification is suggested. 
 
2.2.8 Statistical analysis 
The statistical method is used to prioritize or select the proteins believed to be 
important for the clinical or biological question. From 5000-10 000 proteins identified 
in a high quality shotgun proteomics experiment, the statistical analysis narrows down 
to a few (10-100) proteins of interest. In papers I and IV, a multivariate PLS model is 
used as the basis for selection and evaluation of proteins. PLS regression is a 
multivariate method for assessing a relationship between a descriptor matrix X and a 
response matrix Y. In the context of the proteomics data, the protein expression data is 
the descriptor matrix and the sample class is the response matrix.  
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PLS models are generated by finding latent variables (PLS components) in the data 
that maximize the covariance between the response variable (Y) and a linear 
combination of the predictor variables (X). PLS Discriminant Analysis (PLS-DA) is a 
classical PLS regression but where the response variable is categorical, indicating the 
classes of the samples. PLS-DA has often been used for classification and 
discrimination problems [169, 170]. An extension to the supervised PLS regression 
method is Orthogonal projection to latent structures (OPLS) [171]. OPLS uses 
information in the Y matrix to separate the X matrix into correlated (predictive) and 
uncorrelated (non-predictive) orthogonal information. Those changes often lead to an 
improved interpretability, while the predictivity is the same as for the PLS model.   
 
PLS models can be used for regression, classification, prediction and variable selection. 
The strength of PLS lies in the interpretation of the model and the variables importance 
for the model. The usage of PLS in the current study has been mainly to select proteins 
of interest. For this the Variable Importance on Projection (VIP) was used, which is a 
summary of the importance of a variable on the model [120]. 
 
2.2.8.1 Statistical model validation 
The PLS models are validated by cross-validation in papers I and IV. In paper I, a 
double cross-validation scheme is used [172]. The inner loop consisted of a bootstrap 
cross-validation [173] for the optimization of PLS model parameters and variable 
selection. The outer loop was a 5-fold cross-validation used to evaluate the 
performance of the optimal model. The variable selection was based on mean VIP 
score as well as stability over cross-validation rounds. In paper IV, the subnetwork 
PLS model is evaluated based on a leave-one-out (LOO) cross-validation. In general, 
LOO should be used with care since leaving out only one sample might lead to over-
optimistic results caused by other similar samples in the training set. The choice of 
LOO for the subnetwork model was based on that one of the proteomics datasets 
consisted of very few samples (3+3).   
 
The model performance can be assessed by several different measures. R2 and Q2 are 
commonly used for multivariate PLS and OPLS models. R2 is a measure of how well 
the model describes the data, thus it is based on the training dataset. R2X is the fraction 
of X variance explained by the model, while R2Y is the fraction of Y variance 
explained by the model. Q2 is based on the test set during cross-validation and is a 
measure of how well the model predicts “new” data. The subnetwork PLS model in 
paper IV was evaluated based on Q2. Other frequently used measures of model 
performance are sensitivity and specificity, which are also calculated from the 
prediction of a test set. Sensitivity, or true positive rate, is the probability of a positive 
test among positive samples. Specificity, or true negative rate, is the probability of a 
negative test among negative samples. The success measure used to evaluate the PLS 
model in paper I was the geometric mean of sensitivity and specificity. 
 
2.2.8.2 Subnetwork methods 
In paper IV, protein expression values from MS analysis were mapped to protein 
interaction data. A network based PLS model was then developed to identify 
subnetworks differentially regulated between phenotypes. Several different approaches 
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to identify differently regulated subnetworks, based on expression data, have been 
published over the last years. Most methods have two components in common: a 
scoring method to measure the discriminative strength of the subnetwork and a search 
algorithm to find the highest scoring subnetworks. The scoring methods used have been 
basic scoring schemes such as absolute difference [140], p-values [174] and mutual 
information [138], as well as more complicated scoring strategies based on principal 
components [175], decision trees [176] and support vector machines [177].  
 
The scoring approaches can roughly be divided into univariate and multivariate [139]. 
A univariate scoring approach assesses the regulation of each node individually and 
then searches for subnetworks with enrichment in regulated nodes. A multivariate 
scoring approach on the other hand, assesses regulation for all nodes in the subnetwork 
together. The scoring in paper IV was based on a multivariate PLS model, evaluated 
by Q2 based on a LOO cross-validation on the samples. The possible variables in the 
PLS model were thus restricted by the links in the network. A greedy search algorithm 
[138] was used to search for the optimal scoring subnetwork initiated from each 
starting node. 
 
The generated subnetworks each have a score based on the Q2 of the PLS model. The 
significance level of the scores has to be assessed by randomization. Random networks 
were created by node permutation [178] in paper IV to define a score threshold for 
significant subnetworks.  
 
2.2.8.3 Network data 
To increase the protein network size in paper IV, a meta database (STRING) of protein 
associations was used. STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins) is a resource for retrieving all information on functional links between 
proteins [179, 180]. The associations in STRING are derived from high-throughput 
experimental data, from text-mining of databases and literature, and from predictions 
based on genomic context analysis. STRING combines and scores interaction data from 
the various sources for a large number of organisms, and also transfers information 
between the organisms via orthologous protein pairs. The confidence score for each 
link, reflects how likely a given association is. The database currently covers over 5 
million proteins from 1133 organisms (Version 9.1). For paper IV, the network was 
restricted to only Human interactions with a confidence score higher than 900, 
considered to be highly confident (Figure 8). 
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Figure 8. Network of protein interactions from STRING. The nodes are proteins and the edges 
between them are functional couplings. The network is restricted to only Human interactions with a 
confidence score higher than 900. The network consists of 113306 interactions and 9542 proteins. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Paper I 
In this work, we demonstrated a multivariate meta-analysis of 2DE proteomics data 
from human prostate and colon tumours, with the aim to identify common and unique 
protein patterns. The bioinformatics workflow developed included merging of the two 
datasets followed by dealing with pre-processing of data and handling of missing 
values and the development of a multivariate PLS model for prediction and variable 
selection. The missing values posed a big challenge in analysing the 2DE data from two 
very different tumour types. Many missing values existed in the merged data set, which 
affected the modelling result. With the purpose of finding proteins with common 
expression patterns over the two tumour types, the analysis was restricted to those 
proteins that were expressed in both data sets. 
 
This study utilized PLS-DA to build predictive models and to select variables important 
for separating between the classes normal and tumour, independent of tissue origin. The 
PLS model development and variable selection was rigorously evaluated using a double 
cross-validation scheme (Figure 9). The mean success rate over bootstrap rounds in the 
outer loop was plotted for varying number of variables and number of PLS components 
and used to find an optimal PLS model.  
 
The optimal number of variables and PLS components in the PLS model is a trade-off. 
The number of selected variables should be small enough to enable further validation of 
the proteins using more targeted methods for measuring the expression levels in a 
larger cohort of clinical samples. At the same time, the number of variables has to be 
large enough to achieve a good predictive PLS model. Regarding the PLS components, 
too few components might not be enough to explain the data while too many might lead 
to an over-fitted model, describing the noise in the data. For the current study, three 
PLS components and 50 variables were selected as optimal PLS parameter settings.  
 
 
Figure 9. Double cross-validation scheme. In the inner loop, PLS model parameters and variables are 
estimated based on a bootstrap cross-validation. Based on performance of the PLS models and stability of 
variables over bootstrap rounds, the optimal parameters and final set of variables are selected. Model 
performance of the optimized parameters and selected variables are then evaluated on the held-out test set 
in the outer loop. The outer loop is repeated within a 5-fold cross-validation procedure.   
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The final selection of variables was based on stability over the bootstrap validation 
rounds in the inner loop. The reasoning is that the stable variables are thought to 
represent variables generally good for predicting the classes and not specific for certain 
subsets of the data. Despite such different tissues in the data, there were around 40 
variables (from the lists of 50 variables) that were selected in at least 50% of the 
bootstrap rounds. The stable variables were together with the optimized PLS model 
applied to predict the held-out test sets in the outer loop. The average prediction success 
over five cross-validation rounds was 0.93 (±0.06), for the PLS model discriminating 
between normal and tumour samples, independent on tissue type.  
 
The combined prostate-colon model was compared to individual prostate and colon 
PLS models (including only variables present in both datasets). The resulting lists of 
stable variables for the three models were compared in a Venn diagram (Figure 10). 
The figure reveals that most variables are unique to the models and few overlaps are 
identified, only three variables overlap between all three models. As many as 46 of the 
variables from the meta-analysis of prostate-colon did not show up in the individual 
models, while 25 and 27 variables were unique to the prostate and colon models 
respectively. The 46 variables unique to the meta-model represent proteins whose 
expression levels discriminate between normal and tumour samples independent of 
tissue type in this study, i.e. a common protein profile for malign tumour types. The 
variables unique to the individual models on the other hand represent proteins that are 
specific for the certain tumour types prostate and colon. This result shows the potential 
of a meta-analysis to identify proteins not found when analysing the data sets in 
separate. The current study only included two tumour types, and can mainly function as 
a proof of concept, but the potential of including more tumour types is apparent.  
 
 
Figure 10. Overlap of variables selected in different models. Venn diagram showing overlap between 
stable variables selected using the prostate-colon meta-model and individual prostate and colon models.  
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2.3.2 Paper II 
In this study, we developed a methodology for improved protein quantification in 
shotgun proteomics data and introduced a way to assess quantification quality. Peptide 
and protein identification and quantification was compared between different MS 
platforms, as well as between different loaded peptide amounts and different sample 
separation methods. See experimental setup for the standard dataset in Figure 7. 
 
The quality of the peptide quantification was evaluated by scaled root mean square 
error (RMSEs). The RMSEs includes both bias and variance and measures the average 
magnitude of the error per peptide over all eight iTRAQ channels. The RMSEs values 
were plotted against intensity, revealing that the error in quantitation is intensity 
dependent and decreases as the peptide intensity increase. To be able to study only the 
variance in the peptide quantifications, the peptide intensities were normalized to equal 
sample median and the relative standard deviation (RSD) calculated. RSD and RMSEs 
shows the same trend with decreasing RSD when intensity increases. The RSD was 
overall smaller than RMSEs showing that there is a bias in the un-normalized data. 
Further investigations exhibited a small bias (around 5%) towards one. In our settings, 
the variance thus seems to be the largest contributor to the error.  
 
RMSEs was calculated to compare instruments, loaded peptide amount and separation 
method. The peptide quantities from the Orbitrap and MALDI have rather similar 
RMSEs values, while QTOF peptide quantities have much higher RMSEs values. The 
number of identified peptides also varied largely with the MS instrument, the Orbitrap 
generated more than five times as many identifications as the MALDI and QTOF. The 
results on protein level mainly confirm the results from the comparison on the peptide 
level; the Orbitrap performs best followed by MALDI and then QTOF. Orbitrap 
identifies approximately four times more proteins than the other instruments do. In 
summary, increasing the amount of loaded peptides as well as pre-fractionating the 
sample by IPG-IEF results in the best performance for the Orbitrap, both when it comes 
to error levels at the peptide and protein level as well as number of identifications. 
 
It is crucial that the quantitative information on the peptide level is correct when 
summarizing to protein level quantity. In this study we therefore evaluated two 
alternative methods to improve protein quantities: either by removing low intensity 
peptides prior to summarizing to protein quantity or by using all peptides but weight 
them according to their uncertainty (determined by their absolute intensity, high weight 
corresponding to high intensity) when summarizing to protein quantity. The weighted 
mean and filter methods were compared to using all peptides for the calculation of a 
regular mean as well as to the weighted mean method in the Mascot software. The 
measured protein ratios were compared to the expected ratios and the relative error was 
calculated for all protein quantification approaches (Figure 11A). It can be seen in the 
figure that more proteins are calculated with a lower relative error when using the 
weighted mean as compared to the other methods. 
 
In Figure 11B, the relative error of protein quantity is related to protein weight 
(calculated as the mean of the peptide weights derived from the intensity) for proteins 
with different number of peptides. Seen in the figure, the relative error of the protein 
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quantity is very much dependent on the number of peptides used for quantification of 
the protein. For proteins with few peptides, the intensity of the peptides (visualized by 
protein weight) influence the relative error strongly, while for proteins with large 
number of peptides the intensity of the peptides has smaller impact on error. Even at 
low protein weight the relative error is rather small for proteins with multiple peptides 
for quantification. Hence, peptides with low intensity can be important for creating a 
robust protein quantity. 
 
 
Figure 11. A: Comparison of methods to calculate protein quantities based on peptides. The bars 
represent percentage of protein ratios passing different relative error thresholds, for weighted protein 
mean, regular protein mean/median, filtered protein mean/median and Mascot weighted protein mean. B: 
Impact of the number of peptides per protein on quantification error. The relative error of weighted 
protein quantity is plotted against protein weight for proteins with different number of peptides. Lines 
represent smoothed 95% upper limit of relative error. The protein weight is calculated as the mean of 
peptide weights. 
 
In the current study, the weight is calculated based on an internal training set (technical 
duplicate) for each run. An internal training set for the weights is to prefer, according to 
our results, since different experimental settings will affect the data quality differently. 
As an outcome of these results, we suggest including one technical duplicate in each 
iTRAQ run so weights can be calculated specifically for every new data set, and then 
be applied to the remaining biological iTRAQ samples. We further suggest that a plot 
(11B) and corresponding table with weights and errors are created for each dataset 
based on the duplicate in the experiment. This can then be used to set a threshold on 
protein weights to ascertain reliable protein ratios, which will be especially important 
for proteins with one or a few peptides for quantification. 
 
The method of calculating weights based on an internal training set was applied to 
independent datasets of cell line samples and lung cancer tissue samples. The weighted 
mean performs slightly better than the regular mean, confirming the results from the 
original standard dataset. The improvement is rather modest, around 5% for the lung 
cancer tissue samples. Still, we believe this is an important improvement, as it 
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corresponds to around 90 more proteins in the clinical dataset with accurate 
quantification (<5% relative error), which can be essential for discovering biomarkers. 
 
2.3.3 Paper III 
In this study we developed SpliceVista, a tool for splice variant identification and 
visualization based on MS proteomics data. By mining data from an alternative splicing 
database (EVDB) and mapping MS identified peptides to known splice variants, 
SpliceVista can identify splice variant specific peptides and perform splice variant 
specific quantitative analysis. 
 
There are four main parts of SpliceVista: Data pre-process, in which all PSMs are 
assigned a gene symbol from its protein ID and grouped into peptides. Download, 
where SpliceVista retrieves known splice variants in the EVDB database and translated 
sequences of these splice variants from GenBank. Mapping, in which all identified 
peptides are grouped by gene based on the downloaded data. In particular, for each 
gene all the identified peptides are mapped to the gene’s known splice variants. 
Genomic and transcriptional position of each peptide is reported in the output file. 
Visualization, where the data from previous steps is used for visualizing the exon 
structures of each splice variant of the protein and the transcriptional position of 
identified peptides. In addition, if PQPQ [162] is used, the peptide clusters based on 
quantitative information are visualized allowing connection between splice specific 
peptides and detected quantitative peptide clusters. See example in Figure 12.     
 
 
Figure 12. Example output figure of SpliceVista. The top panel displays the exon structure of the gene. 
The mid panel displays the transcriptional positions of identified peptides. If PQPQ is applied, each 
peptide is assigned to a cluster in which all peptides show correlated quantitative pattern. The different 
clusters are coloured and the peptides are coloured accordingly and plotted in line with the cluster it 
belongs to. In the bottom panel, the quantitative patterns of the different clusters are drawn in the same 
order as in the mid panel. The bars represent the mean intensity ratio of all peptide spectra matches 
(PSMs) for each unique peptide, the standard deviation is indicated by vertical lines (error bars). 
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To evaluate the potential and limitations of shotgun MS based proteomics for splice 
variant specific analysis, we performed in silico trypsin digestion of the human 
proteome (Ensembl 63). 18% of the tryptic peptides uniquely map to a splice variant 
and 22% of the splice variants have unique tryptic peptides. Given that a splice variant 
is present in the sample, the identification by shotgun proteomics is dependent on 
mainly two factors. First it depends on whether or not the splice variant has unique 
sequences to make it possible to identify. According to the theoretical calculation, up to 
22% of human splice variants can thus be identified in theory by peptide centric MS by 
assigning splice variant specific peptides (SVSP). Secondly, it depends on the protein 
sequence coverage in the MS experiment. The higher the protein sequence coverage is, 
the higher the chance of identifying a splice variant by its unique peptides. 
 
To test the applicability of the method on proteomics data generated by shotgun MS, 
we used SpliceVista to analyse human cancer cell line that had been analysed both as 
whole cell lysate, as well as through sub-cellular fractionation. 607 splice variants and 
1680 SVSPs were identified in the whole cell fraction. After combining splice variants 
identified in the three subcellular fractions, the number of unique splice variants 
identified was 939 and the number of SVSPs was 2983. By subcellular fractionation, 
the number of splice variants and SVSP identifications were increased by 55% and 
78% respectively. Theoretically, the chance of identifying one splice variant specific 
peptide is higher if there are more peptides per protein identified. As expected, the data 
demonstrated that using subcellular fractionation, we can increase splice variant 
specific peptide and splice variant identifications due to increased protein coverage.  
 
We performed three different quantitative analyses on the genes with splice variants 
identified in the cell line dataset: gene centric, protein centric and splice variant specific 
analysis (Figure 13). In the gene centric analysis, the relative expression level of a gene 
is calculated by the mean ratio of all PSMs identified for this gene. In protein centric 
analysis, the conventional way, the relative expression level of a protein is calculated 
by the mean ratio of all PSMs for this protein. In splice variant specific analysis, PSMs 
specific (uniquely mapped) to one splice variant are grouped and the relative expression 
level of the splice variant is calculated as the mean ratio of those PSMs only. 
 
The genes in Figure 13 exemplify cases where there is a large difference between gene 
centric, protein centric and splice variant specific analysis. Since more than 90% of 
genes can undergo alternative splicing, there is a potential risk of averaging out the 
differences of differentially regulated splice variants when doing protein centric 
analysis if the protein contains peptides shared among protein isoforms. With 
SpliceVista, we are able to quantify splice variants specifically and compare to gene 
centric and protein centric analysis. 
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Figure 13. Heat map showing comparison of fold change between gene centric, protein centric and splice 
variant specific analysis at different time points. 
 
2.3.4 Paper IV 
In this work, we developed a network based analysis workflow for proteomics data to 
identify subnetworks with different activity between groups of samples. The idea was 
to shift focus from individual proteins showing differential expression to protein 
subnetworks with altered activity. 
 
The outline of the subnetwork method is shown in Figure 14. The network data was 
extracted from the STRING database. Each of the proteins mapped to the network data 
was used as a starting node for the search algorithm, searching for the optimal scoring 
subnetwork. The search stops if any of the termination criteria are met; addition of 
neighbours does not improve the score over a defined threshold, 5%, or the size of the 
subnetwork is larger than 20 (to keep the search local), or if the protein node lacks 
additional neighbours. The resulting subnetwork scores were shown to be dependent on 
network size and the score distribution is thus not homogeneous.  
 
 
Figure 14. Schematic outline of the subnetwork analysis. The protein expression data is mapped onto the 
protein interaction network from STRING. A greedy search algorithm is searching through the mapped 
network for the highest scoring subnetwork. The score is based on predictive success (Q2) of a 
multivariate PLS model, evaluated by leave-one-out cross-validation on the samples. The optimal 
subnetworks and corresponding measurements of subnetwork score and size are saved in a new data 
matrix. 
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For evaluating the significance of optimal subnetworks, the results were compared to 
randomized input data. The network randomization was done by permuting the nodes 
500 times, searching for optimal subnetworks and scoring them by the PLS model. 
Score threshold for any given significance level could then be calculated based on the 
fraction of random subnetworks exceeding certain score threshold. As was seen also for 
the real network, the score is dependent on subnetwork size, with a bias towards higher 
score for larger subnetworks. Since the score is clearly dependent on subnetwork size, 
the score threshold (corresponding to 5% FDR) was calculated for each subnetwork 
size separately. The resulting significant subnetworks were merged into one if they 
overlapped with at least two proteins. The largest significant subnetwork for the clinical 
data is seen in Figure 15. 
 
 
Figure 15. The figure depicts the largest significant subnetwork for the clinical dataset. The border of the 
nodes are coloured by fold-change of mutated versus wild-type, red is up-regulated in mutated and green 
is down-regulated in mutated. The individual log2 expression values are shown as a bargraph under each 
node, the mutated samples as dark grey bars and the wild-type samples as light grey bars. The four most 
enriched terms for the subnetwork are illustrated as a pie chart in each node, grey means that none of the 
terms are annotated to this node. The figure was generated in Cytoscape, an open source software 
platform for network visualisation [181]. 
 
The significant subnetworks were used as a basis for enrichment analysis, using gene 
sets from the MSigDB (Molecular Signatures Database) [182]. MSigDB is a collection 
of annotated gene sets, derived from a number of different databases as well as from 
computational approaches. Hypergeometric testing adjusted for multiple tests was 
performed to identify enriched terms. Only terms with at least three hits in the 
subnetwork and enriched by an adjusted p-value of less than 0.05 were considered 
(FDR 5%). The four terms with the best coverage (proportion of proteins in subnetwork 
annotated to it) for the largest subnetwork for the clinical dataset are shown in Figure 
15. 
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For comparison, a univariate statistical analysis as well as a regular multivariate PLS 
analysis was performed on the datasets in this study. The univariate analysis generated 
no significant proteins at a 5% FDR level, for any of the tested datasets. In a complex 
study of human cell lines or clinical samples one might expect the effect on proteins to 
be on several proteins, which might not be picked up by a univariate statistical test. The 
regular PLS model on the other hand suffers from other problems: How to select the 
optimal set of variables and how to interpret the results. In the current study, PLS 
analysis on the clinical dataset generated a list of around 80 significant proteins. The 80 
proteins were mapped to the STRING network. The proteins were spread throughout 
the whole network with no visible clustering and very few links connecting the 
significant proteins. The proteins from regular PLS analysis were also subject to 
enrichment analysis, which resulted in no significantly enriched terms at a 5% FDR 
level. This also indicated that the proteins are not biologically related and represent 
proteins from very different processes. The subnetwork analysis on the other hand, 
generates functionally related proteins that are linked to each other in the network. This 
study is still on-going, the statistical model need to be further validated. The significant 
subnetworks also need to be validated biologically, both to see that the interactions 
occur under the conditions studied as well as to verify that the protein subnetworks can 
be picked up in a larger sample cohort and that they have a biological meaning. 
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2.4 GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
Extract more information from available data 
The work in paper I aimed at showing how additional valuable information can be 
extracted from existing 2DE data by performing a meta-analysis cross different tumour 
types. By the workflow for meta-analysis developed in paper I, we identified a 
common protein profile for two malign tumour types, which was not identified when 
analysing the data sets separately. By combining tumour data sets the identified protein 
profiles could potentially be used in addressing several clinical questions which are 
difficult to answer based on analysis of a single study. Common proteins profiles could 
be changes related to oncogenic processes and could thus be used to better understand 
tumour biology and address common issues such as malignity, severity, survival and 
risk of metastasis. The meta-analysis should be used in combination with the separate 
analysis to distinguish the common protein changes from the unique. The specific 
proteins that are differently expressed only in a certain tissue type, could help to 
provide a more certain tumour diagnosis. 
 
A similar meta-analysis approach could have several possible uses. We have in the lab 
now gathered a large amount of mass spectrometry based proteomics datasets, both on 
human cancer cell lines and on clinical material from several different tumour types. As 
the approach is not limited to 2DE per se, the data can be used to draw general 
conclusions on large scale protein expression in different cell lines and in different 
clinical material to find unique and common patterns. The approach could also be 
extended to publically available datasets; the amount of MS based proteomics datasets 
in public domain resources are increasing [183-185]. 
 
Similarly, another use of available in-house datasets is to investigate issues such as 
technical and biological variation and overlaps between experimental runs in terms of 
quantities and identifications. By studying the in-house generated datasets we can build 
up better and more detailed knowledge of our experimental system and better 
understand the limitations and possibilities. Before planning a new experiment one may 
consider if the question can be answered by already existing datasets, just by 
approaching it in a different way. 
  
Another important aspect related to using the full potential of each dataset is the 
amount of data not explained by current peptide identifications by database search (as 
much as 70% of generated spectra are not explained). This is partly due to low quality 
spectra of course, but there is also a big limitation in current database search methods to 
identify protein isoforms and modified proteins. By developing new methods, like 
SpliceVista in paper III, and re-searching available datasets, we can further explore the 
data. The analysis in paper III, demonstrates detection and splice variant specific 
quantitation of 939 splice variants on protein level in the cell line dataset, hence 
improving data output compared to conventional analysis. Nevertheless, the method is 
limited to identify known splice variants reported in the public repositories. The current 
version of the EVDB database contains around 80 000 splice variants. Considering that 
more than 90% of human genes may undergo alternative splicing this probably 
represents only a small fraction of the total protein splice variants. Furthermore, since 
splicing variants are temporal and tissue specific the databases are likely to be biased 
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towards well studied tissues and conditions. Despite limitations, by taking into account 
splice variant information, we have the potential to make new findings, from available 
data as well as from new data. 
 
Importance of high quality quantitative data 
In mass spectrometry based proteomics we are almost always interested in the quantity 
of the proteins, not only the identity. The goal of proteomics discovery research is often 
to measure quantitative changes in protein levels between two or more different 
conditions. It is thus crucial to know what quantitative data we can trust. Bad quality 
quantitative data will have effects at every step in the following data analysis and it will 
most likely lead to failure in the validation of the findings. To provide solid scientific 
data and to save time and money we would like to achieve as correct quantitative 
information as possible as well as to know the limitations of the quantification. The 
purpose of paper II was to generate a basis for the decision of what protein quantities 
are reliable and find a way for accurate and precise protein quantification. We 
developed a methodology that improved protein quantification in shotgun proteomics 
analysis of complex biological samples and introduced a way to assess quantification 
for proteins with few peptides.  
 
The result in the current study is a guideline to assess the quality of protein quantities. 
The methodology we developed in paper II is applicable to both other datasets as well 
to other labelling methods. We suggest including a technical duplicate in each 
experiment, so that the peptide weights can be calculated based on the errors and 
variations in the current experiment. By using two iTRAQ channels for the technical 
replicate samples, six iTRAQ channels could be used for other biological samples. This 
would mean to sacrifice at most one extra channel for a technical replicate. Replicates 
in the experiment can also be used for other purposes, for example in the down-stream 
statistical analysis of finding differently expressed proteins. To be able to interpret the 
data we need at least duplicate samples of the control samples to account for biological 
and technical variation. We further suggested that the generated figures and tables 
could be used as a guideline to set a threshold on protein weights to ascertain reliable 
protein ratios. This will be especially important for proteins with one or a few peptides 
for quantification. Generally, proteins with few peptides detected as well as low 
abundant proteins have the largest relative errors and represent the biggest challenge 
when it comes to reliable protein quantification. For our own lab, I think it is important 
that this methodology is included in the standard data analysis pipeline.  
 
Another important aspect when considering the reliability of the protein quantities is 
the difficulty of current database search methods to infer protein isoforms. In MS based 
proteomics, the peptides identified for a protein could potentially come from different 
splice variants with similar sequences. If several splice variants of a gene exist in a 
sample, the quantitative data for that gene/protein is a mixture of all splice variants. 
During traditional gene centric or protein centric quantitative data analysis, the 
quantitative data can thus be wrong. The quantitative data will be very different 
depending on the abundance of the splice variants in the sample, if there exist one or a 
few highly abundant splice variants, the quantitative data can be dominated by this. The 
tool developed in paper III, SpliceVista, provides the possibility to do splice variant 
centric analysis at the protein level. The quantitation of a splice variant is done by 
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quantitation of its splice variant specific peptides, i.e. peptides uniquely mapped to one 
splice variant. This was in several cases shown to be very different from the gene 
centric or protein centric analysis. The method allows for identification of splice variant 
specific quantitative changes related to for example clinical questions.  
 
Considerations in the statistical analysis 
A critical problem when working with datasets of 5000-10 000 variables but very few 
samples, as often the case in discovery proteomics, is the risk of false positives. Further 
complicating the problem is that the clinical data harbours a large amount of biological 
variation and that we expect the biological changes of interest to be rather small. All 
those factors lead to risks of making false discoveries in the statistical analysis. A false 
discovery will lead to failure during the validation of the finding. 
 
One important step to protect against false discoveries is rigorous validations of the 
statistical model. For univariate methods, methods for correction for multiple tests are 
applied. For multivariate methods we have in paper I and IV used cross-validation to 
assess the models performance on “new” samples not seen by the model during the 
optimisation and training phase. This is done to make sure the model and the variables 
selected are general and not performing well only for a certain subset of the samples. In 
the best of scenarios the statistical model and selected variables are tested on a 
completely different set of samples. This is most often not possible due to few samples 
available. The second best scenario would be to perform two layers of cross-validation, 
an inner layer to optimise the model and select the variables and an outer layer to test 
the model and variables on the held out test set. In paper I a double cross-validation 
scheme was used, and the final variables were selected based on stability over cross-
validation rounds in the inner layer. In paper IV this was not possible since the datasets 
consisted of too few samples. I believe that the subnetwork method would be improved 
by including a second layer of cross-validation. Some samples could be set aside and 
the optimal subnetworks would be tested on those. This would both give a better 
assessment of the predictive performance of the subnetwork as well as an idea of the 
stability of the subnetwork optimisation process. The subnetworks found to be 
significant independent on training set used would represent the most stable ones, most 
likely to perform well also on a different sample cohort. 
 
A rather recent paper [186] discussed the problem of multiple testing adjustment and 
FDR in multivariate methods. The use of multiple testing correction is more or less 
standard in univariate methods, while for multivariate methods no such standard exist. 
The publication suggests a method to assess FDR for molecular signatures, which 
should be valid for any multivariate statistical method for variable selection and 
prediction. The problem is that the multivariate model is often optimized with regards 
to predictive success, while the study showed that signatures that yield high prediction 
success may still have a high FDR. If the purpose of using multivariate methods is to 
select variables (discovery) as in the current study, rather than to predict new samples, 
one should consider taking this into account and select variables based on FDR and 
stability rather than prediction success. Traditional multivariate methods for 
classification based on molecular profiles suffer from the fact that there are often 
several alternative sets of variables yielding the same predictive outcome, thus making 
it difficult to select the most biologically relevant set of variables for reproducible 
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performance in a different sample cohort. By basing the selection on FDR and stability 
rather than prediction success this problem might be reduced. This will hopefully also 
lead to a higher rate of success during validation of the finding. 
 
One has to keep in mind though, that the statistical validation is not the same as the 
biological validation. The biological validation is crucial to verify the changes detected 
by the statistical method, preferably in a larger sample cohort, and also to verify that the 
finding has a biological meaning. But a sound validation of the statistical model to 
protect against false discoveries would at least give a chance for the biological 
validation to be successful. With high rate of false discoveries in the discovery phase 
one cannot expect the biological validation to be successful since the finding is due to 
chance rather than a real biological or clinical effect.  
 
A completely different, and perhaps complementary, approach to improve statistical 
power and reduce risk of false discoveries is to increase the number of samples. The 
strength of the experimental setup we currently use in the lab is the analytical depth, 
enabling the identification and quantification of the low abundant proteins. But this is 
on the cost of the number of samples that can practically be run in an experiment. We 
thus need alternative more high-throughput approaches to be able to increase sample 
size. One option would be to analyse fewer of the fractions from IPG-IEF, thereby 
decreasing runtime on the mass spectrometer. Another option is to do label free 
analysis, but this method suffers from limitations in identification overlap between 
runs. We are currently working on methods to improve the stability and overlap of 
consecutive label free runs. 
 
Network based methods 
To move from univariate methods to multivariate statistical methods in the study of 
cancer proteomics is motivated by that complex biological processes not are driven by 
individual proteins. One natural continuation in this reasoning is to incorporate pathway 
and network data in the statistical analysis to let the interaction data steer the 
multivariate model, as in paper IV. The motivation for this would be that the set of 
proteins acting in a biological process are not random, rather they act in interaction with 
other proteins in signalling pathways and network modules. The results generated in 
paper IV pointed towards potential advantages of a subnetwork based PLS model as 
compared to a regular PLS model. The resulting significant proteins were subsets of 
linked proteins with several biological processes and functions in common. The regular 
PLS analysis on the other hand, resulted in a set of proteins that all represented very 
different biological processes and functions. Subnetwork based signatures can thus 
more readily provide a model of the biological mechanisms studied and be easier to 
interpret, since they represent functionally coupled proteins rather than a collection of 
sparse proteins. 
 
Another strength of the network based methods is that by restricting the selection of 
variables by the network, the risk of false and unstable discoveries might be decreased. 
The network data provide robustness and prior knowledge that is used to filter the 
possible variables. This also makes the selection of optimal variables easier, since the 
problem with multivariate models is often that several models give the same predictive 
success thus making it difficult to select the optimal set of variables.  
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The network based models are still a quite new approach though and there is probably 
room for improvement. One possible additional feature that the subnetwork methods 
need to account for is the inter-individual patient variability, as suggested in Sandberg 
et al. [187]. Not all patients can be expected to have changes in all of the proteins in a 
network. The network method thus needs to allow for a few of the proteins in the 
network not to be differentially expressed in a subset of the samples [188, 189]. 
Furthermore, the interaction (edge) between the proteins can also be subject to change 
and can be as important for the phenotype as the changes of protein (node) levels. 
Several subnetwork methods accounting for changes in edge activity has been 
presented over the last few years [140, 175, 190, 191]. An additional weakness of the 
subnetwork approach is the network itself, which relies on databases of protein 
interaction data. The number of proteins and links covered in current databases are far 
from being complete and furthermore they are likely to be error prone and biased 
towards well studied parts of the interactome [192, 193]. So the network based methods 
are expected to be more correct as the databases gets larger and higher quality.  
 
From data to results to biological and clinical knowledge 
We generate terabytes of data per week with the latest instruments and techniques, but 
there is still a gap in how to move from data to knowledge in a robust and sound way. 
To enable the leap from data to biological meaning, system based approaches 
integrating multiple data types are necessary. The integration of vast experimental data 
on different levels of the system, DNA/RNA/protein/metabolite, together with 
knowledge of interactions and pathways are key aspects to be able to create better 
models of disease and healthy phenotype [135-137, 194-199]. We have seen in 
numerous publications, and at conferences, that the predictive performance and stability 
of expression data can be improved by incorporating interactome data, see review in 
[139]. Studies have shown that even though single genes are not conserved in cancer 
(and other disease), the pathways are. The information held in affected pathways, could 
also be used to find new drug targets and alternative treatment regimens based on 
knowledge from other diseases affecting the same pathway. A challenge is to find 
clever and systematic ways to use all the prior knowledge available in public databases 
and to integrate those with molecular expression data. This is of course not an easy 
task, but it is important to use the vast amount of knowledge already collected. One 
further challenge of building models of complex systems is to find a balance between 
accurate models, possible models and useful models, which are often not the same 
thing. 
   37 
3 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Proteiner är cellens arbetshästar; DNA:t har instruktionen och RNA:t är budbäraren 
medan proteinerna utför själva arbetet. Proteiner är inblandade i alla biologiska 
processer i cellen. Proteomet är benämningen av alla proteiner i t.ex. en organism eller 
en vävnad. Det humana protetomet omfattar alltså alla proteiner som finns i människan. 
Det humana genomet (alla gener) består av ca 20 000 gener, det humana proteomet 
däremot uppskattas till omkring totalt 1 000 000 proteiner. Det beror på att en gen kan 
ge upphov till flera olika proteiner. Detta sker både genom så kallad alternativ 
splitsning där en gen klipps ihop till olika proteiner och genom post-translationella 
modifieringar där ett protein får olika kemiska grupper (modifieringar) på sig. Den 
enorma komplexiteten gör proteomet svårstuderat. Proteomet är dessutom dynamiskt 
och i konstant förändring - det varierar med tid, celltyp och omgivande betingelser. 
Studien av proteomet; dess sammansättning, uttrycksnivå, struktur, funktion och 
interaktioner; kallas för proteomik. En vanlig metod för storskalig analys av proteiner 
är att använda masspektrometri. Genom masspektrometri får man information om vilka 
proteiner ett prov innehåller samt den mängd av proteinet som finns i provet. I en så 
kallad ”shotgun proteomics” analys klipps proteinerna först ner till peptider (fragment 
av protein) för att sedan analyseras i masspektrometern. 
 
Detta arbete handlar om cancerproteomik, alltså storskalig studie av förändringar i 
proteomet som är relaterade till cancer. Syftet med vår forskning är dels att hitta 
proteiner som kan hjälpa oss bättre förstå cancerbiologin, t.ex. varför det uppstår 
resistens mot ett läkemedel, dels hitta proteiner som kan användas som biomarkörer. En 
biomarkör är exempelvis ett protein som kan mätas vid provtagning och vars nivå säger 
något om patientens sjukdom. T.ex. kan en diagnostisk biomarkör användas för att 
ställa en diagnos medan en prediktiv biomarkör kan användas för att förutsäga hur en 
patient kommer att svara på en viss behandling. För trots stora framgångar inom 
cancerdiagnos och behandling är cancer fortfarande den ledande dödsorsaken i världen. 
Med hjälp av nya biomarkörer hoppas vi kunna förbättra överlevnaden hos 
cancerpatienter. En tidigt ställd diagnos är avgörande för att kunna sätta in behandling i 
ett tidigt skede. Genom att skräddarsy behandlingen efter patienten kan man undvika 
många biverkningar och slippa förlora värdefull tid på behandlingar med dålig effekt. 
 
Cancer är en komplex sjukdom; flera olika gener är påverkade i utvecklingen från 
normal cell till cancercell. Den senaste tekniken för att studera genomet och proteomet 
har ingett mycket hopp om att kunna hitta nya, bättre biomarkörer. Tyvärr har 
forskningen inom dessa områden ännu inte genererat biomarkörer som kommit till 
klinisk nytta. Hindren har varit många, speciellt har flera storskaliga studier på senaste 
tiden kunnat visa på svårigheten med att finna stabila biomarkörer baserat på enstaka 
gener. När studierna upprepats i en annan provkohort har inte samma gener varit 
förändrade. Man har dock sett att liknande signalvägar (pathways) är påverkade. Trots 
att det inte är exakt samma gener så är det alltså i samma del av det cellulära systemet 
som förändringen skett. Det har således föreslagits att det länge använda uttrycket 
”Cancer is a disease of the genes” kanske borde ändras till ”Cancer is a disease of the 
pathways”. 
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För att kunna använda proteomikdata på bästa sätt och för att kunna dra giltiga 
slutsatser från resultaten krävs en rigid kvalitetskontroll och avancerad dataanalys. 
Först och främst måste vi veta att den kvantitativa datan är pålitlig, alltså att det mått vi 
har på mängden protein är korrekt. Vi måste även ha rätt statistiska metoder för att 
analysera datan, för att inte riskera att plocka upp proteiner som felaktigt klassificerats 
som signifikant ändrade. Vi måste även utveckla metoder för att integrera 
proteinkvantiteter med annan kunskap om t.ex. interaktioner mellan proteiner (protein-
nätverk). Senaste tidens studier har tydligt visat att DNA, RNA och proteiner inte 
räcker för att fullt förstå sjukdomsmekanismer, eftersom biologiska funktioner är 
mycket mer komplexa än summan av de individuella komponenterna. För att kunna 
skapa bättre modeller av sjukdom och hälsa krävs en systembaserad analys, där 
integration av de olika typerna av data är i fokus. 
 
Det huvudsakliga syftet med mitt doktorandprojekt har varit att utveckla robusta 
metoder för att välja ut nyckelproteiner, nätverk och signalvägar som är relevanta för 
kliniska frågeställningar, med proteomikdata som utgångspunkt. Projektet har gått från 
att fastställa lämpliga gränser för kvantifiering, till förbehandling av data samt 
metodutveckling för statistisk dataanalays mot målet att generera ett set av 
nyckelproteiner. Jag har även utvecklat systembaserade metoder för att integrera olika 
typer av data i syfte att förbättra möjligheten att skapa biologiskt och kliniskt relevant 
information från proteomikdatan.   
 
I studie I utvecklade vi en meta-analys för att kunna koppla samman befintlig data från 
humana prostata- och kolontumörer. Syftet var att identifiera proteiner som skiljer 
mellan normala och tumörprover oberoende av vävnadsursprung. Detta arbetsflöde 
möjliggjorde upptäckten av en gemensam proteinprofil för två maligna tumörtyper, 
som inte varit möjligt att fastställa då tumörerna analyserades separat.  
 
Syftet med studie II var att skapa beslutsunderlag för vilka proteinkvantiteter (nivåer) 
som är tillförlitliga och att hitta ett sätt för noggrann och exakt proteinkvantifiering. Vi 
utvecklade en metod för förbättrad proteinkvantifiering och introducerade ett sätt att 
bedöma kvaliteten på kvantifieringen av proteiner. Den experimentella designen och de 
utvecklade algoritmerna minskade det relativa felet i proteinkvantifiering av komplexa 
biologiska prover. 
 
I studie III utvecklade vi SpliceVista, ett verktyg för identifiering och visualisering av 
alternativa splitsningsvarianter i masspektrometridata. Genom att matcha identifierade 
proteiner mot kända splitsningsvarianter, kan SpliceVista identifiera peptider som är 
specifika för en viss splitsningsvariant och upptäcka differentiellt uttryckta 
splitsningsvarianter på proteinnivå. 
 
I studie IV utvecklade vi en nätverksbaserad analys för proteomikdata för att identifiera 
subnätverk med olika aktivitet mellan grupper av prover. Tanken är att flytta fokus från 
enskilda proteiner som visar differentiellt uttryck till protein-subnätverk med förändrad 
aktivitet. Metodiken tillämpades på flera av våra kliniska dataset. Genom att studera 
proteinuttryck i kontexten av protein-nätverk kunde vi detektera skillnader på en 
systemnivå och förenkla tolkningen av resultaten från cancerstudier. 
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